Angelini Farmacéutica clinical trials
A country office of Angelini Pharma
The registry lists 6 studies whose lead sponsor is Angelini Farmacéutica. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 22, 2022.
Registry sponsor names on this page
- Angelini Farmacéutica6 studies
Something wrong with this grouping? Tell us on the Angelini Pharma page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Angelini Pharma studies →
- A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.TerminatedNCT04742413
Sponsor listed in the registry: Angelini Farmacéutica
- Dalbavancin in Real Clinical Practice in SpainCompletedNCT04485676
Sponsor listed in the registry: Angelini Farmacéutica
- Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)CompletedNCT03435120
Sponsor listed in the registry: Angelini Farmacéutica
- N680S Polymorphism of the FSHR Gene and Its Relationship With the Type of Gonadotropin Used in COSStatus unknownNCT04122729
Sponsor listed in the registry: Angelini Farmacéutica
- Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care UnitsCompletedNCT02840500
Sponsor listed in the registry: Angelini Farmacéutica
- Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative IntentCompletedNCT02836379
Sponsor listed in the registry: Angelini Farmacéutica